Primary FDA-Approved Indications
Label‑supported pediatric uses include acute otitis media (AOM), streptococcal pharyngitis/tonsillitis, skin and skin structure infections, and urinary tract infections.
Acute Otitis Media (AOM)
FDA ApprovedChildren ≥6 monthsLabel
Alternative when first‑line agents are unsuitable.
Treatment Duration
Standard: 10 days (Range: 7–10 days)
Evidence Sources
Cefaclor — FDA DailyMed ()
GAS Pharyngitis/Tonsillitis
FDA ApprovedChildren and adolescentsLabel
Alternative when penicillin or amoxicillin cannot be used; confirm GAS diagnosis.
Treatment Duration
Standard: 10 days
Evidence Sources
CDC — Strep Throat Clinical Guidance ()
Uncomplicated Skin and Skin Structure Infections
FDA ApprovedChildren and adolescentsLabel
Use organism‑directed therapy and local guidance.
Treatment Duration
Standard: 7–10 days
Evidence Sources
Cefaclor — FDA DailyMed ()
Uncomplicated Urinary Tract Infections
FDA ApprovedChildren and adolescentsLabel
Use guided by organism and susceptibility.
Treatment Duration
Standard: 7–10 days
Evidence Sources
Cefaclor — FDA DailyMed ()